Journal for ImmunoTherapy of Cancer: 10 (5)

Editorial

Celebrating a decade of the Journal for ImmunoTherapy of Cancer
(20 May, 2022)
Pedro J Romero, James L Gulley, Patrick Hwu, Mary Dean, Samuel Million-Weaver

Basic tumor immunology

Original research: Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization (25 May, 2022)
Dandan Sheng, Wei Ma, Rui Zhang, Lei Zhou, Qiaodan Deng, Juchuanli Tu, Weilong Chen, Fuchuang Zhang, Nailong Gao, Mengxue Dong, Dong Wang, Fengkai Li, Yin Liu, Xueyan He, Shengzhong Duan, Lixing Zhang, Tong Liu, Suling Liu
Original research: Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation (23 May, 2022)
Antonio Sorrentino, Ayse Nur Menevse, Tillmann Michels, Valentina Volpin, Franziska Christine Durst, Julian Sax, Maria Xydia, Abir Hussein, Slava Stamova, Steffen Spoerl, Nicole Heuschneider, Jasmin Muehlbauer, Katharina Marlene Jeltsch, Anchana Rathinasamy, Melanie Werner-Klein, Marco Breinig, Damian Mikietyn, Christian Kohler, Isabel Poschke, Sabrina Purr, Olivia Reidell, Catarina Martins Freire, Rienk Offringa, Claudia Gebhard, Rainer Spang, Michael Rehli, Michael Boutros, Christian Schmidl, Nisit Khandelwal, Philipp Beckhove
Original research: Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells (20 May, 2022)
David Noyes, Arup Bag, Saheed Oseni, Jon Semidey-Hurtado, Ling Cen, Amod A Sarnaik, Vernon K Sondak, Dennis Adeegbe
Original research: Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity (19 May, 2022)
Pierre-Louis Bernard, Rebecca Delconte, Sonia Pastor, Vladimir Laletin, Cathy Costa Da Silva, Armelle Goubard, Emmanuelle Josselin, Rémy Castellano, Adrien Krug, Julien Vernerey, Raynier Devillier, Daniel Olive, Els Verhoeyen, Eric Vivier, Nicholas D Huntington, Jacques Nunes, Geoffrey Guittard
Original research: Mitoribosomal defects aggravate liver cancer via aberrant glycolytic flux and T cell exhaustion (17 May, 2022)
Byong-Sop Song, Ji Sun Moon, Jingwen Tian, Ho Yeop Lee, Byeong Chang Sim, Seok-Hwan Kim, Seul Gi Kang, Jung Tae Kim, Ha Thi Nga, Rui Benfeitas, Yeongmin Kim, Sanghee Park, Robert R. Wolfe, Hyuk Soo Eun, Minho Shong, Sunjae Lee, Il-Young Kim, Hyon-Seung Yi
Original research: Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway (16 May, 2022)
Yue Zhuo, Shujun Li, Wei Hu, Yu Zhang, Yufan Shi, Faxue Zhang, Jian Zhang, Juan Wang, Meijuan Liao, Jiahao Chen, Huiling Qian, Dejia Li, Chengcao Sun
Original research: Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation (16 May, 2022)
Lin Zhu, Xinwei Kuang, Guanxiong Zhang, Long Liang, Dandan Liu, Bin Hu, Zuozhong Xie, Hui Li, Hong Liu, Mao Ye, Xiang Chen, Jing Liu
Original research: Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment (12 May, 2022)
Angela Pizzolla, Simon Paul Keam, Ismael A Vergara, Franco Caramia, Niko Thio, Minyu Wang, Nikolce Kocovski, Daniela Tantalo, Jafar Jabbari, George Au-Yeung, Shahneen Sandhu, David E Gyorki, Alison Weppler, Maurizio Perdicchio, Grant A McArthur, Anthony T Papenfuss, Paul Joseph Neeson

Clinical/translational cancer immunotherapy

Original research: Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study (31 May, 2022)
Lucia Carril-Ajuria, Aude Desnoyer, Maxime Meylan, Cécile Dalban, Marie Naigeon, Lydie Cassard, Yann Vano, Nathalie Rioux-Leclercq, Salem Chouaib, Benoit Beuselinck, Sylvie Chabaud, Janice Barros-Monteiro, Antoine Bougoüin, Guillaume Lacroix, Irelka Colina-Moreno, Florence Tantot, Lisa Boselli, Caroline De Oliveira, Wolf Herve Fridman, Bernard Escudier, Catherine Sautes-Fridman, Laurence Albiges, Nathalie Chaput-Gras
Original research: Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer (27 May, 2022)
Wei Wei, Xiaohua Ban, Fan Yang, Jibin Li, Xiaqin Cheng, Rong Zhang, Xin Huang, Yongwen Huang, Qiaqia Li, Ya Qiu, Min Zheng, Xiaofeng Zhu, Jundong Li
Original research: Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials (25 May, 2022)
Espen Basmo Ellingsen, Elin Aamdal, Tormod Guren, Wolfgang Lilleby, Paal F Brunsvig, Sara M Mangsbo, Steinar Aamdal, Eivind Hovig, Nadia Mensali, Gustav Gaudernack, Else Marit Inderberg
Original research: Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma (23 May, 2022)
Pavlina Chuntova, Akane Yamamichi, Tiffany Chen, Rohini Narayanaswamy, Sebastien Ronseaux, Christine Hudson, Adriana E Tron, Marc L Hyer, Megan Montoya, Abigail L Mende, Takahide Nejo, Kira M Downey, David Diebold, Min Lu, Brandon Nicolay, Hideho Okada
Original research: Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial (20 May, 2022)
Kanwal P Raghav, Bettzy Stephen, Daniel D Karp, Sarina A Piha-Paul, David S Hong, Dipti Jain, Dilichukwu O Chudy Onwugaje, Abdulrahman Abonofal, Anneleis F Willett, Michael Overman, Brandon Smaglo, Ryan W Huey, Funda Meric-Bernstam, Gauri R Varadhachary, Aung Naing
Original research: Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies (20 May, 2022)
Mathieu Larroquette, Jean-Philippe Guegan, Benjamin Besse, Sophie Cousin, Maxime Brunet, Sylvestre Le Moulec, François Le Loarer, Christophe Rey, Jean-Charles Soria, Fabrice Barlesi, Alban Bessede, Jean-Yves Scoazec, Isabelle Soubeyran, Antoine Italiano
Original research: Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial (18 May, 2022)
Jessica Hochberg, Jaclyn Basso, Qiuhu Shi, Liana Klejmont, Allyson Flower, Kristina Bortfeld, Lauren Harrison, Carmella van de Ven, Chitti Moorthy, Humayun Islam, Perry Gerard, Stephan Voss, Mitchell S Cairo
Original research:
A_2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models
(17 May, 2022)
Apple Hui Min Tay, Rubén Prieto-Díaz, Shiyong Neo, Le Tong, Xinsong Chen, Valentina Carannante, Björn Önfelt, Johan Hartman, Felix Haglund, Maria Majellaro, Jhonny Azuaje, Xerardo Garcia-Mera, Jose M Brea, Maria I Loza, Willem Jespers, Hugo Gutierrez-de-Teran, Eddy Sotelo, Andreas Lundqvist
Original research: Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma (17 May, 2022)
Katarina Pinjusic, Olivier Andreas Dubey, Olga Egorova, Sina Nassiri, Etienne Meylan, Julien Faget, Daniel Beat Constam
Original research:
CD4⁺ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
(17 May, 2022)
Minglu Xiao, Luoyingzi Xie, Guoshuai Cao, Shun Lei, Pengcheng Wang, Zhengping Wei, Yuan Luo, Jingyi Fang, Xingxing Yang, Qizhao Huang, Lifan Xu, Junyi Guo, Shuqiong Wen, Zhiming Wang, Qing Wu, Jianfang Tang, Lisha Wang, Xiangyu Chen, Cheng Chen, Yanyan Zhang, Wei Yao, Jianqiang Ye, Ran He, Jun Huang, Lilin Ye
Original research: Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial (17 May, 2022)
Federica Riccardo, Lidia Tarone, Mariateresa Camerino, Davide Giacobino, Selina Iussich, Giuseppina Barutello, Maddalena Arigoni, Laura Conti, Elisabetta Bolli, Elena Quaglino, Irene Fiore Merighi, Emanuela Morello, Alfredo Dentini, Soldano Ferrone, Paolo Buracco, Federica Cavallo
Original research: Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade (16 May, 2022)
Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, Jean-Pascal Machiels, Jose Luis Perez Gracia, F Stephen Hodi, Alvaro Taus, Maria Martinez Garcia, Valentina Boni, Joseph P Eder, Navid Hafez, Ryan Sullivan, David Mcdermott, Stephane Champiat, Sandrine Aspeslagh, Catherine Terret, Anna-Maria Jegg, Wolfgang Jacob, Michael A Cannarile, Carola Ries, Konstanty Korski, Francesca Michielin, Randolph Christen, Galina Babitzki, Carl Watson, Georgina Meneses-Lorente, Martin Weisser, Dominik Rüttinger, Jean-Pierre Delord, Aurelien Marabelle
Original research: Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma (11 May, 2022)
Gino Kim In, Aparna Nallagangula, Jacob Seung Choi, Lisa Tachiki, Matthew J Blackburn, Stephen Capone, Kathryn B Bollin, Daniel Y. Reuben, Keisuke Shirai, Sandy Zhang-Nunes, Omar Ragab, Alicia Terando, Jenny C. Hu, Han Lee, Shailender Bhatia, Sunandana Chandra, Jose Lutzky, Geoffrey Thomas Gibney
Original research: Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study (10 May, 2022)
Yuan-Yuan Qu, Zhongquan Sun, Weiqing Han, Qing Zou, Nianzeng Xing, Hong Luo, Xuepei Zhang, Chaohong He, Xiao-Jie Bian, Jinling Cai, Chunxia Chen, Quanren Wang, Ding-Wei Ye
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation (9 May, 2022)
Elizabeth M Holland, John C Molina, Kniya Dede, Daniel Moyer, Ting Zhou, Constance M Yuan, Hao-Wei Wang, Maryalice Stetler-Stevenson, Crystal Mackall, Terry J Fry, Sandhya Panch, Steven Highfill, David Stroncek, Lauren Little, Daniel W Lee, Haneen Shalabi, Bonnie Yates, Nirali Shah

Immunotherapy biomarkers

Original research: Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients (18 May, 2022)
Sara Bruschini, Matteo Pallocca, Eleonora Sperandio, Lorenzo D’Ambrosio, Francesca Ascenzi, Claudia De Vitis, Valentina Salvati, Antonella Esposito, Simona Di Martino, Francesca De Nicola, Francesca Paolini, Luigi Fattore, Gabriele Alessandrini, Francesco Facciolo, Maria Laura Foddai, Massimiliano Bassi, Federico Venuta, Michela D’Ascanio, Alberto Ricci, Antonio D’ Andrilli, Christian Napoli, Luigi Aurisicchio, Maurizio Fanciulli, Erino Angelo Rendina, Gennaro Ciliberto, Rita Mancini
Original research: Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens (17 May, 2022)
Sofia Khazan-Kost, Gal Cafri, Dganit Melamed Kadosh, Navit Mooshayef, Sumit Chatterji, Dan Dominissini, Sigal Manor, Bracha Zisser, Limor Broday, Efrosiniia Talalai, Anat Shemer, Oranit Zadok, Efrat Ofek, Amir Onn, Arie Admon, Michael Peled
Original research:
Intrahepatic inflammatory IgA⁺PD-L1^high monocytes in hepatocellular carcinoma development and immunotherapy
(16 May, 2022)
Pil Soo Sung, Dong Jun Park, Pu Reun Roh, Kyoung Do Mun, Sung Woo Cho, Gil Won Lee, Eun Sun Jung, Sung Hak Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Jonghwan Choi, Jaegyoon Ahn, Seung Kew Yoon
Original research: Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model (15 May, 2022)
Koichi Azuma, Huihui Xiang, Tomoyuki Tagami, Rika Kasajima, Yumiko Kato, Sachise Karakawa, Shinya Kikuchi, Akira Imaizumi, Norikazu Matsuo, Hidenobu Ishii, Takaaki Tokito, Akihiko Kawahara, Kenta Murotani, Tetsuro Sasada, Yohei Miyagi, Tomoaki Hoshino
Original research: Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome (12 May, 2022)
Mark A J Gorris, Lieke L van der Woude, Leonie I Kroeze, Kalijn Bol, Kiek Verrijp, Avital L Amir, Jelena Meek, Johannes Textor, Carl G Figdor, I Jolanda M de Vries
Original research: NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer (5 May, 2022)
Sen Yan, Han Zeng, Kaifeng Jin, Fei Shao, Zhaopei Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Jiejie Xu

Immune cell therapies and immune cell engineering

Original research: Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma (20 May, 2022)
Zhuo Yu, Yuyao Li, Yue Li, Jinghao Zhang, Man Li, Longshan Ji, Yifei Tang, Yanxi Zheng, Jianguo Sheng, Qiucheng Han, Fu Li, Jianfeng Guo, Lingtai Wang, Xuehua Sun, Yueqiu Gao, Hai Feng
Original research: The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL (17 May, 2022)
Kai Rejeski, Ariel Perez, Gloria Iacoboni, Olaf Penack, Veit Bücklein, Liv Jentzsch, Dimitrios Mougiakakos, Grace Johnson, Brian Arciola, Cecilia Carpio, Viktoria Blumenberg, Eva Hoster, Lars Bullinger, Frederick L Locke, Michael von Bergwelt-Baildon, Andreas Mackensen, Wolfgang Bethge, Pere Barba, Michael D Jain, Marion Subklewe

Letter

Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng et al
(31 May, 2022)
Vidya Sankar Viswanathan, Mohammadhadi Khorrami, Khalid Jazieh, Pingfu Fu, Nathan Pennell, Anant Madabhushi
Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
(31 May, 2022)
Jieling Zheng, Bin Zhang

Oncolytic and local immunotherapy

Original research: Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy (27 May, 2022)
Xiaoyi Jiang, Jian Wang, Xichen Zheng, Zhida Liu, Xinyu Zhang, Yuwei Li, Jonathan Wilhelm, Jun Cao, Gang Huang, Jinlan Zhang, Baran Sumer, Jayanthi Lea, Zhigang Lu, Jinming Gao, Min Luo
Original research: Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors (24 May, 2022)
Yinghan Su, Jiang Li, Weidan Ji, Gang Wang, Lin Fang, Qin Zhang, Lin Ang, Min Zhao, Yuan Sen, Lei Chen, Junnian Zheng, Changqing Su, Lunxiu Qin
Original research: Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma (20 May, 2022)
Taylor J Aiken, Amy K Erbe, Lauren Zebertavage, David Komjathy, Arika S Feils, Matthew Rodriguez, Ashley Stuckwisch, Stephen D Gillies, Zachary S Morris, Jen Birstler, Alexander L Rakhmilevich, Paul M Sondel
Original research: TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy (16 May, 2022)
Miriam Valenzuela-Cardenas, Cody Gowan, Parker Dryja, Mee Y Bartee, Eric Bartee

Position article and guidelines

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma (31 May, 2022)
Ramaswamy Govindan, Charu Aggarwal, Scott J Antonia, Marianne Davies, Steven M Dubinett, Andrea Ferris, Patrick M Forde, Edward B Garon, Sarah B Goldberg, Raffit Hassan, Matthew D Hellmann, Fred R Hirsch, Melissa L Johnson, Shakun Malik, Daniel Morgensztern, Joel W Neal, Jyoti D Patel, David L Rimm, Sarah Sagorsky, Lawrence H Schwartz, Boris Sepesi, Roy S Herbst

Review

Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment (31 May, 2022)
Lihong Wang, Louisa S Chard Dunmall, Zhenguo Cheng, Yaohe Wang
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells (17 May, 2022)
Sainiteesh Maddineni, John L Silberstein, John B Sunwoo
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models (16 May, 2022)
Emmanuel Donnadieu, Maik Luu, Miriam Alb, Brigitte Anliker, Silvia Arcangeli, Chiara Bonini, Biagio De Angelis, Rashmi Choudhary, David Espie, Anne Galy, Cam Holland, Zoltán Ivics, Chahrazade Kantari-Mimoun, Marie Jose Kersten, Ulrike Köhl, Chantal Kuhn, Bruno Laugel, Franco Locatelli, Ibtissam Marchiq, Janet Markman, Marta Angiola Moresco, Emma Morris, Helene Negre, Concetta Quintarelli, Michael Rade, Kristin Reiche, Matthias Renner, Eliana Ruggiero, Carmen Sanges, Hans Stauss, Maria Themeli, Jan Van den Brulle, Michael Hudecek, Monica Casucci
Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside? (16 May, 2022)
Sonia Guedan, Maik Luu, Delphine Ammar, Paula Barbao, Chiara Bonini, Philippe Bousso, Christian J Buchholz, Monica Casucci, Biagio De Angelis, Emmanuel Donnadieu, David Espie, Beatrice Greco, Richard Groen, Johannes B Huppa, Chahrazade Kantari-Mimoun, Bruno Laugel, Mary Mantock, Janet L Markman, Emma Morris, Concetta Quintarelli, Michael Rade, Kristin Reiche, Alba Rodriguez-Garcia, Juan Roberto Rodriguez-Madoz, Eliana Ruggiero, Maria Themeli, Michael Hudecek, Ibtissam Marchiq

Main menu

Table of contents

May 2022 - Volume 10 - 5

Editorial

Basic tumor immunology

Clinical/translational cancer immunotherapy

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Letter

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

May 2022 - Volume 10 - 5

Editorial

Basic tumor immunology

Clinical/translational cancer immunotherapy

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Letter

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction